Raised plasma aldosterone and natriuretic peptides in atrial fibrillation

Cardiology

Volumn 108, Issue 1, 2007, Pages 35-39

  Dixen, Ulrik ^a   Ravn, Lasse ^b   Soeby Rasmussen, Christian ^c   Paulsen, Anders Wallin ^c   Parner, Jan ^c   Frandsen, Erik ^b   Jensen, Gorm B ^c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Aldosterone; Atrial fibrillation; Natriuretic peptides; Renin angiotensin aldosterone system

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE; AMINO TERMINAL PRO ATRIUM NATRIURETIC PEPTIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLECAINIDE; PROPAFENONE; SOTALOL; SPIRONOLACTONE; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RHYTHM; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LINEAR REGRESSION ANALYSIS; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINUS RHYTHM; TREATMENT OUTCOME;

ADULT; AGED; ALDOSTERONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROBABILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34347333473     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095671     Document Type: Article

References (23)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952.
2. Friberg J, Buch P, Scharling H, Gadsboll N, Jensen GB: Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666-672.
3. Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and pre-disposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
4. Nishino M, Hoshida S, Tanouchi J, Ito T, Kato J, Iwai K, Tanahashi H, Hori M, Yamada Y, Kamada T: Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation. Am J Cardiol 2000;85:1451-1454.
5. Redfield MM, Kay GN, Jenkins LS, Mianulli M, Jensen DN, Ellenbogen KA: Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000;75:790-795.
6. Tepper D: Frontiers in congestive heart failure: tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Congest Heart Fail 2000;6:284.
7. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS: Utility of Btype natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-385.
8. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, Morrisey R, Garcia A, Chiu A, De Maria A: Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-374.
9. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU: Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001;88:906-909, A8.
10. Jourdain P, Bellorini M, Funck F, Fulla Y, Guillard N, Loiret J, Thebault B, Sadeg N, Desnos M: Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study. Eur J Heart Fail 2002;4:263-267.
11. Tuinenburg AE, van Veldhuisen DJ, Boomsma F, Van Den Berg MP, De Kam PJ, Crijns HJ: Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am J Cardiol 1998;81:1207-1210.
12. Dixen U, Joens C, Parner J, Rasmussen V, Pehrson SM, Jensen GB: Prolonged signal-averaged P wave duration after elective cardioversion increases the risk of recurrent atrial fibrillation. Scand Cardiovasc J 2004;38:147-151.
13. Brilla CG, Matsubara LS, Weber KT: Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-16A.
14. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090-2098.
15. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-336.
16. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-380.
17. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719.
18. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:705-711.
19. Heidbuchel H: A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy? Eur Heart J 2003;24:2077-2078.
20. Rowland NE, Morian KR: Roles of aldosterone and angiotensin in maturation of sodium appetite in furosemide-treated rats. Am J Physiol 1999;276:R1453-R1460.
21. Burnier M, Brunner HR: Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 1992;13:28-33.
22. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
23. Wozakowska-Kaplon B, Opolski G: Concomitant recovery of atrial mechanical and endocrine function after cardioversion in patients with persistent atrial fibrillation. J Am Coll Cardiol 2003;41:1716-1720.